Pharmena S.A. (PHR.WA)
PLN 4.0
(-3.15%)
PLN 4.0
(-3.15%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | -32.76 Million PLN | -25.0% |
| 2022 | 10.85 Million PLN | -8.34% |
| 2021 | 11.84 Million PLN | 6.48% |
| 2020 | 11.12 Million PLN | -36.98% |
| 2019 | 17.64 Million PLN | 102.13% |
| 2018 | 8.72 Million PLN | -20.43% |
| 2017 | 10.97 Million PLN | -13.25% |
| 2016 | 12.64 Million PLN | -18.25% |
| 2015 | 15.46 Million PLN | 11.54% |
| 2014 | 13.86 Million PLN | 21.94% |
| 2013 | 11.37 Million PLN | 22.07% |
| 2012 | 9.31 Million PLN | 235.95% |
| 2011 | 2.77 Million PLN | 1.15% |
| 2010 | 2.74 Million PLN | -28.56% |
| 2009 | 3.83 Million PLN | 87.62% |
| 2008 | 2.04 Million PLN | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.06 Million PLN | -97.45% |
| 2024 Q2 | 781 Thousand PLN | 1.31% |
| 2023 Q1 | 2.9 Million PLN | -12.97% |
| 2023 Q3 | -36 Million PLN | -5507.48% |
| 2023 Q2 | -642 Thousand PLN | -122.1% |
| 2023 Q4 | 41.87 Million PLN | 216.33% |
| 2023 FY | 8.14 Million PLN | -25.0% |
| 2022 Q3 | 2.62 Million PLN | -5.37% |
| 2022 Q2 | 2.77 Million PLN | 31.38% |
| 2022 Q4 | 3.33 Million PLN | 27.07% |
| 2022 FY | 10.85 Million PLN | -8.34% |
| 2022 Q1 | 2.11 Million PLN | -33.26% |
| 2021 Q2 | 3.7 Million PLN | 62.3% |
| 2021 FY | 11.84 Million PLN | 6.48% |
| 2021 Q4 | 3.16 Million PLN | 17.96% |
| 2021 Q3 | 2.68 Million PLN | -27.6% |
| 2021 Q1 | 2.28 Million PLN | -35.68% |
| 2020 Q1 | 2.77 Million PLN | -28.29% |
| 2020 Q2 | 2.65 Million PLN | -4.15% |
| 2020 Q4 | 3.55 Million PLN | 66.09% |
| 2020 FY | 11.12 Million PLN | -36.98% |
| 2020 Q3 | 2.13 Million PLN | -19.56% |
| 2019 Q2 | 7.63 Million PLN | 198.55% |
| 2019 Q4 | 3.86 Million PLN | 7.84% |
| 2019 FY | 17.64 Million PLN | 102.13% |
| 2019 Q1 | 2.55 Million PLN | -14.62% |
| 2019 Q3 | 3.58 Million PLN | -53.03% |
| 2018 Q3 | 1.91 Million PLN | -9.71% |
| 2018 Q4 | 2.99 Million PLN | 56.32% |
| 2018 FY | 8.72 Million PLN | -20.43% |
| 2018 Q2 | 2.12 Million PLN | 25.12% |
| 2018 Q1 | 1.69 Million PLN | -42.47% |
| 2017 FY | 10.97 Million PLN | -13.25% |
| 2017 Q2 | 3.3 Million PLN | 34.72% |
| 2017 Q1 | 2.45 Million PLN | -27.61% |
| 2017 Q3 | 2.26 Million PLN | -31.28% |
| 2017 Q4 | 2.94 Million PLN | 29.93% |
| 2016 Q3 | 3.04 Million PLN | -3.4% |
| 2016 FY | 12.64 Million PLN | -18.25% |
| 2016 Q4 | 3.38 Million PLN | 11.34% |
| 2016 Q2 | 3.14 Million PLN | 2.51% |
| 2016 Q1 | 3.07 Million PLN | -44.79% |
| 2015 Q1 | 3.47 Million PLN | -15.11% |
| 2015 Q3 | 3.17 Million PLN | -2.88% |
| 2015 Q4 | 5.56 Million PLN | 75.46% |
| 2015 FY | 15.46 Million PLN | 11.54% |
| 2015 Q2 | 3.26 Million PLN | -6.02% |
| 2014 Q4 | 4.09 Million PLN | 42.99% |
| 2014 Q2 | 2.71 Million PLN | -35.57% |
| 2014 Q1 | 4.2 Million PLN | 34.33% |
| 2014 FY | 13.86 Million PLN | 21.94% |
| 2014 Q3 | 2.86 Million PLN | 5.57% |
| 2013 Q2 | 3.31 Million PLN | 37.45% |
| 2013 Q4 | 3.13 Million PLN | 24.74% |
| 2013 FY | 11.37 Million PLN | 22.07% |
| 2013 Q1 | 2.41 Million PLN | -13.38% |
| 2013 Q3 | 2.51 Million PLN | -24.35% |
| 2012 FY | 9.31 Million PLN | 235.95% |
| 2012 Q3 | 2.67 Million PLN | 0.0% |
| 2012 Q4 | 2.78 Million PLN | 4.11% |
| 2011 FY | 2.77 Million PLN | 1.15% |
| 2010 FY | 2.74 Million PLN | -28.56% |
| 2009 FY | 3.83 Million PLN | 87.62% |
| 2008 FY | 2.04 Million PLN | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bioceltix S.A. | 15.38 Million PLN | 312.97% |
| BIOTON S.A. | 57.55 Million PLN | 156.925% |
| Captor Therapeutics Spolka Akcyjna | 79.91 Million PLN | 140.999% |
| Mabion S.A. | 59.52 Million PLN | 155.047% |
| Molecure S.A. | 31.73 Million PLN | 203.261% |
| NanoGroup S.A. | 7.82 Million PLN | 518.634% |
| Poltreg S.A. | 15.47 Million PLN | 311.729% |
| Pure Biologics Spólka Akcyjna | 29.14 Million PLN | 212.425% |
| Ryvu Therapeutics S.A. | 4.73 Million PLN | 791.537% |
| Synthaverse S.A. | 26.35 Million PLN | 224.326% |
| Urteste S.A. | 5.96 Million PLN | 649.011% |